Drugs / Avagacestat
Avagacestat
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT01002079 | Aug → Oct 2010 | Alzheimer disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT01042314 | Jan → Apr 2010 | Alzheimer disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00979316 | Sep 2009 → Feb 2010 | Alzheimer disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00828646 | Oct 2008 → Jul 2009 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00726726 | Aug → Oct 2008 | Alzheimer disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT01454115 | Jun 2007 → Mar 2009 | Alzheimer disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00890890 | May 2009 → Jul 2013 | Alzheimer disease | Bristol-Myers Squibb | Terminated | No outcome recorded |
| Comparator or background therapy6 trials | ||||||
| Phase 1 | NCT01079819 Comparator | Apr → Dec 2010 | Alzheimer disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT01057030 Comparator | Mar → Jun 2010 | Alzheimer disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT01039194 Comparator | Jan → Apr 2010 | Alzheimer disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00901498 Comparator | May → Jul 2009 | Alzheimer disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00860275 Comparator | Apr → Jun 2009 | Alzheimer disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT00810147 Comparator | Feb 2009 → Jun 2010 | Alzheimer disease | Bristol-Myers Squibb | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2011-07-20 | Bristol-Myers Squibb | Results Data on Bristol-Myers Squibb’s Investigational Treatment for Alzheimer’s Disease Demonstrate Potential Therapeutic Window at Doses Below 100 mg in Phase II Safety and Tolerability Study bms.com ↗
Bristol-Myers Squibb Company (NYSE: BMY) today announced the results of a Phase II study evaluating the safety and tolerability of the investigational gamma secretase inhibitor BMS-708163 in patients with mild-to-moderate Alzheimer’s disease. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2011-07-20 | Bristol-Myers Squibb | Data on Bristol-Myers Squibb’s Investigational Treatment for Alzheimer’s Disease Demonstrate Potential Therapeutic Window at Doses Below 100 mg in Phase II Safety and Tolerability Study bms.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | avagacestat | “BMS-708163 (avagacestat) is an oral GSI designed for selective inhibition of Aβ synthesis currently in development for the treatment of mild to moderate and predementia AD.” PMID 22381714 ↗ Feb 2012 |
| Known as | BMS-708163 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01039194 ↗ |
| Known as | BMS-708163-01 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1090771 ↗ |
| Action | Inhibit | “the γ-secretase inhibitor avagacestat in PDAD” PMID 26414022 ↗ Nov 2015 |
| Modality | Small molecule | — CHEMBL1090771 ↗ |
| Route | Oral | “Capsules, Oral” NCT00726726 ↗ |